FGT-2734

FGT-2734 is a novel, small-molecule dual inhibitor of farnesyltransferase (FTase) and geranylgeranyltransferase-I (GGTase-I). Developed by researchers at Virginia Commonwealth University, including Said Sebti, it is designed to block protein isoprenylation, a critical post-translational modification required for the membrane localization and activation of signaling proteins such as Ras and Rho GTPases. By inhibiting both FTase and GGTase-I, FGT-2734 aims to overcome the limitations of selective farnesyltransferase inhibitors, which often fail due to alternative prenylation of targets by GGTase-I. Preclinical research has demonstrated that FGT-2734 can attenuate IL-33-induced cytokine production in mast cells, suggesting potential therapeutic utility in treating allergic asthma and other mast cell-driven inflammatory diseases.